Evidence map›Paper›PMID 34816598›Full record

ArticleObesity (Silver Spring, Md.)2022

Insulin resistance persists despite a metabolically healthy obesity phenotype.

Kristin K Hoddy, Christopher L Axelrod, Jacob T Mey, Adithya Hari, Robbie A Beyl, Jourdan B Blair, Wagner S Dantas, John P Kirwan

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Obesity (Silver Spring, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05612282 (The Impact of the Distribution of Adipose Tissue on the Occurrence of Metabolic Disorders and and the Level of Cardiopulmonary Fitness), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05612282 completednot on this map

The Impact of the Distribution of Adipose Tissue on the Occurrence of Metabolic Disorders and and the Level of Cardiopulmonary Fitness

TypeobservationalSponsorMedical University of BialystokRan2016 to 2017Enrolled91ConditionsObesity, AbdominalArmsbody composition analysis, anthropometric measurements, Interview questionnaire, biochemical parameters, cardiopulmonary fitness test
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. The Metabolic Syndrome, a Human Disease.International journal of molecular sciences · 2024
    Review
  16. Article
  17. Review
  18. Pharmaceutical efficacy of novel human-originFrontiers in endocrinology · 2023
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kristin K HoddyIntegrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.ORCID 0000-0002-5168-1155
Christopher L AxelrodIntegrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.ORCID 0000-0002-1444-8557
Jacob T MeyIntegrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Adithya HariDepartment of Nuclear Medicine, Montefiore Medical Center, Bronx, New York, USA.
Robbie A BeylIntegrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Jourdan B BlairIntegrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Wagner S DantasIntegrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
John P KirwanIntegrated Physiology and Molecular Medicine Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Pennington Biomedical Research Center · USMontefiore Medical Center · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024989 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 2007 to 2011
$53.7M
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)UM1TR004528 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI GRACE A MCCOMSEY · 2023 to 2026
$32.1M
Research BaseP30DK072476 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2005 to 2026
$26.5M
Training in Botanical Approaches to Combat Metabolic SyndromeT32AT004094 · NCCIH · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI BRANTLEY, PHILLIP J, STEPHENS, JACQUELINE M · 2009 to 2024
$5.7M
Role and Regulation of Skeletal Muscle Mitochondrial Dynamics in Type 2 DiabetesR01DK108089 · NIDDK · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JOHN P. KIRWAN · 2015 to 2026
$4.9M
Age, Exercise, Diet: Effects on Insulin ResistanceR01AG012834 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI KIRWAN, JOHN P. · 2004 to 2008
$1.9M
NCATS NIH HHS UL1 TR002548NCATS NIH HHS UM1 TR004528NCCIH NIH HHS T32 AT004094NCRR NIH HHS 1UL1 RR024989NCRR NIH HHS UL1 RR024989NIA NIH HHS R01 AG012834NIDDK NIH HHS P30 DK072476NIDDK NIH HHS R01 DK108089NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

objectiveMetabolically healthy obesity (MHO) is often defined as the absence of metabolic syndrome in the presence of obesity. However, phenotypic features of MHO are unclear. Insulin sensitivity in MHO was cross-sectionally compared with metabolically unhealthy obesity (MUO) and a reference group of young healthy participants without obesity.

methodsSedentary adults (n = 96) undergoing anthropometric, blood chemistries, maximal aerobic capacity, and euglycemic-hyperinsulinemic clamp measurements were classified by BMI (<25 and ≥30 kg/m

resultsBody weight was similar between MHO and MUO. Body fat (percentage) and high-density lipoprotein cholesterol were higher (p < 0.001), and systolic blood pressure, triglycerides, glucose, and insulin were lower in MHO versus MUO (p < 0.03, all). The MHO group also had lower high-density lipoprotein cholesterol and higher low-density lipoprotein cholesterol, diastolic blood pressure, and insulin compared with the reference. Both the MHO and MUO groups displayed impaired insulin sensitivity compared with the reference control (p < 0.001).

conclusionsParticipants with MHO had distinct clinical measures related to hypertension, lipid metabolism, and glycemic control compared with a healthy reference group. Peripheral insulin resistance in obesity independent of metabolic status portends increased risk for type 2 diabetes in the MHO patient population.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceMetabolic SyndromeObesity, Metabolically BenignBody Mass IndexHumansPhenotypeRisk Factors

Identifiers

PMID34816598
PMCPMC9136885
OpenAlexW3217719229

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.